N
Neuracle Science
Retrocious nervous disorders, such as Alzheimer's disease, have become a major problem in modern society as well as the entry into the aging business
About Neuracle Science
Neuracle Science is a clinical-stage biotechnology company specializing in the development of antibody-based therapeutics for neurodegenerative diseases. The company's research and development efforts are centered on the discovery of novel gene and protein targets, which form the basis for their innovative drug candidates.
Read full description
Operating in the challenging field of neurological disorders, Neuracle Science has established a clear business model focused on the research, development, and subsequent licensing of its therapeutic assets to larger pharmaceutical partners. This strategy is exemplified by their licensing agreement with Reyon Pharmaceutical Co., Ltd., a significant milestone that validates their scientific platform and approach.
Further extending its research capabilities, the company has established a subsidiary, Neuracle Genetics Co., Ltd., to enhance its focus on the genetic basis of neurological diseases. This strategic move allows for a more specialized and in-depth exploration of the underlying causes of these conditions, potentially accelerating the development of more effective treatments. By concentrating on a partnership-based model, Neuracle Science can advance its drug development programs while mitigating the substantial costs and risks associated with late-stage clinical trials and commercialization.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Seoul, South Korea
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 83.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Health and Wellness, Research and Development, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2018
- Capital deployed
- $0
- Preferred round
- CORPORATE SPINOUT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $56M | $225M | Undisclosed | ↗ |
| LATE VCOther financing | May 2024 | $5.6M | $218M | Arcane Investment · Suseong Asset Management · QUAD Ventures | ↗ |
Growth signals
Latest recorded traffic for Neuracle Science is 2.4K monthly website visits, down 27.3% over the last three months. Neuracle Science's team grew 5.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
- AIArcane Investment
- SMSuseong Asset Management
QUAD Ventures
Other known investors1 additional known investor
Korea University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuracle Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuracle Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.